A Prospective Standardized Assessment of People With Cystic Fibrosis and Non-tuberculosis Mycobacteria Pulmonary Disease Undergoing Treatment With Mycobacteriophage (POSTSTAMP)

NTM-OB-17 (PART C)

About 10 people with cystic fibrosis (CF) and persistent Nontuberculosis mycobacteria (NTM) infection despite treatment will be screened to find out if their NTM infection has at least one mycobacteriophage that is effective in killing the mycobacteria. Individuals who are found to have at least one phage will be offered assistance in pursuing FDA approval for treatment via expanded-access Individual New Drug (IND) for compassionate-use. They will receive phage treatment for 1 year along with their guideline-based antibiotics for NTM. Individuals who are not identified as having a phage match will be followed as they continue to receive guideline based antibiotic therapy for 1 year. All subjects, including those who do not have a phage match will continue to be observed for the duration of the study, or about 1 year.

2024-02-05

2026-12-01

2028-12-01

10

Inclusion Criteria: 1. Written informed consent (and assent when applicable) obtained from participant or participant's legal representative 2. Enrolled in the CFF Patient Registry (CFF PR) 3. Be willing to adhere to study procedures in the context of clinical care, and other protocol requirements 4. Male or female participant ≥ 6 years of age at enrollment who are able to reliably expectorate sputum and/or willing to undergo sputum induction (if necessary) 5. Diagnosis of CF consistent with the 2017 CFF Guidelines 6. NTM pulmonary disease on treatment with guideline-based antibiotics for \>12 months without consistent conversion of airway cultures to negative. 7. Physician intention to treat NTM with phage therapy (if susceptible) 8. Be willing and able to continue guideline-based antibiotics for NTM concurrent with phage. 9. Documentation of a sufficient number of NTM cultures with a sufficient proportion of positive cultures in the interval 12 months prior to initiation of phage to allow for a within-subject power ≥0.80 to detect a difference in the percent positive NTM cultures in the interval 6-18 months following initiation of phage. Exclusion Criteria: 1. Pregnant or breastfeeding 2. Prior or ongoing phage therapy for the species of NTM under consideration. 3. History of solid organ or hematological transplantation 4. Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'NTM isolates will be sent to the National Jewish Health (NJH) laboratory for additional testing and will be stored for future research. Specimens will be banked for future research use (blood, sputum, urine, and NTM isolates- including any previous isolates that might be available or previously sent to NJH for analysis). The specimens will be used to learn more about NTM Disease and to learn more about CF.'}, 'enrollmentInfo': {'count': 10, 'type': 'ESTIMATED'}}

2024-02-16